Remdesivir study finally published – an expert in critical care medicine gives us his verdict – ($2,340 per treatment)

So when I go into my hospital this week and am confronted on the wards with patients who are ill with COVID-19, ACTT-1 tells me that, provided I can find remdesivir on the pharmacy shelf, I should be confident to use it in any patients who are receiving oxygen alone, in the hope that they will recover sooner and, more importantly, avoid progression to needing ventilation on intensive care. I should also continue to use dexamethasone as normal, expecting added benefit.

The study also tells me that I should not shut the doors to the intensive care unit just yet. By prescribing remdesivir on top of applying the best treatment available, one in ten patients will continue to deteriorate and die. Remdesivir is not the magic bullet. If one exists, it has yet to be designed.

Source: Remdesivir study finally published – an expert in critical care medicine gives us his verdict